Discounted Cash Flow (DCF) Analysis Levered
Sonoma Pharmaceuticals, Inc. (SNOA)
$0.9816
-0.07 (-6.51%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 16.66 | 18.97 | 18.94 | 18.63 | 12.63 | 11.99 | 11.39 | 10.82 | 10.27 | 9.75 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | -12.44 | -11.72 | -4.59 | -3.38 | -4.25 | -5.10 | -4.84 | -4.60 | -4.36 | -4.14 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -0.19 | -0.10 | -0.21 | -0.18 | -0.14 | -0.11 | -0.11 | -0.10 | -0.10 | -0.09 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | -12.63 | -11.82 | -4.80 | -3.56 | -4.38 | -5.21 | -4.95 | -4.70 | -4.46 | -4.24 |
Weighted Average Cost Of Capital
Share price | $ 0.9,816 |
---|---|
Beta | 1.165 |
Diluted Shares Outstanding | 2.65 |
Cost of Debt | |
Tax Rate | 6.13 |
After-tax Cost of Debt | -0.69% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 9.015 |
Total Debt | 1.37 |
Total Equity | 2.60 |
Total Capital | 3.97 |
Debt Weighting | 34.42 |
Equity Weighting | 65.58 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 16.66 | 18.97 | 18.94 | 18.63 | 12.63 | 11.99 | 11.39 | 10.82 | 10.27 | 9.75 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | -12.44 | -11.72 | -4.59 | -3.38 | -4.25 | -5.10 | -4.84 | -4.60 | -4.36 | -4.14 |
Capital Expenditure | -0.19 | -0.10 | -0.21 | -0.18 | -0.14 | -0.11 | -0.11 | -0.10 | -0.10 | -0.09 |
Free Cash Flow | -12.63 | -11.82 | -4.80 | -3.56 | -4.38 | -5.21 | -4.95 | -4.70 | -4.46 | -4.24 |
WACC | ||||||||||
PV LFCF | -4.67 | -4.19 | -3.77 | -3.39 | -3.04 | |||||
SUM PV LFCF | -20.14 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 5.68 |
Free cash flow (t + 1) | -4.32 |
Terminal Value | -117.46 |
Present Value of Terminal Value | -89.11 |
Intrinsic Value
Enterprise Value | -109.25 |
---|---|
Net Debt | -6.03 |
Equity Value | -103.22 |
Shares Outstanding | 2.65 |
Equity Value Per Share | -38.91 |